Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease
(AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Minimally invasive biomarkers are urgently needed to detect molecular pathology in
frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Here, we show that …

Alzheimer's disease (AD) is characterized by synaptic loss, which can result from
dysfunctional microglial phagocytosis and complement activation. However, what signals …

Cerebral Hemorrhages after t-PA in a Patient Treated with Lecanemab A patient with mild
cognitive impairment who was treated in the extension phase of a trial of lecanemab, an …

Alzheimer's disease (AD) is the leading cause of dementia in older adults. Although AD
progression is characterized by stereotyped accumulation of proteinopathies, the affected …

Worldwide, there are nearly 10 million new cases of dementia annually, of which
Alzheimer's disease (AD) is the most common. New measures are needed to improve the …